ST. LOUIS--(BUSINESS WIRE)--Mediomics, LLC has been awarded a $997,251 Phase II SBIR contract (HHSN261201200081C) from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. This project builds on successful Phase I research, and aims to develop a fully automated in-process analyzer to monitor the titer and quality of recombinant biologics. Using Mediomics’ innovative molecular PINCER® platform, Phase II work will include development of more quantitative antigen-specific assays for antibody titer, affinity, glycosylation and aggregation. This project will culminate with beta-testing by Gallus Biopharmaceuticals, a leading cGMP biologics contract manufacturing organization.